期刊文献+
共找到878篇文章
< 1 2 44 >
每页显示 20 50 100
Antihypertensive drugs and glucose metabolism 被引量:7
1
作者 Christos V Rizos Moses S Elisaf 《World Journal of Cardiology》 CAS 2014年第7期517-530,共14页
Hypertension plays a major role in the development and progression of micro-and macrovascular disease.Moreover,increased blood pressure often coexists with additional cardiovascular risk factors such as insulin resist... Hypertension plays a major role in the development and progression of micro-and macrovascular disease.Moreover,increased blood pressure often coexists with additional cardiovascular risk factors such as insulin resistance.As a result the need for a comprehensive management of hypertensive patients is critical.However,the various antihypertensive drug categories have different effects on glucose metabolism.Indeed,angiotensin receptor blockers as well as angiotensin converting enzyme inhibitors have been associated with beneficial effects on glucose homeostasis.Calcium channel blockers(CCBs)have an overall neutral effect on glucose metabolism.However,some members of the CCBs class such as azelnidipine and manidipine have been shown to have advantageous effects on glucose homeostasis.On the other hand,diuretics andβ-blockers have an overall disadvantageous effect on glucose metabolism.Of note,carvedilol as well as nebivolol seem to differentiate themselves from the rest of theβ-blockers class,being more attractive options regarding their effect on glucose homeostasis.The adverse effects of some blood pressure lowering drugs on glucose metabolism may,to an extent,compromise their cardiovascular protective role.As a result the effects on glucose homeostasis of the various blood pressure lowering drugs should be taken into account when selecting an antihypertensive treatment,especially in patients which are at high risk for developing diabetes. 展开更多
关键词 HYPERTENSION GLUCOSE METABOLISM antihypertensive drugs
下载PDF
Risk Factors Affecting Ischemic Stroke: A Potential Side Effect of Antihypertensive Drugs 被引量:2
2
作者 Kazumitsu Nawata 《Health》 2020年第5期437-455,共19页
Background: Stroke is a worldwide health problem, the world’s second-leading cause of death and third-leading cause of disability. Currently, the majority of stroke patients are ischemic stroke patients. It is necess... Background: Stroke is a worldwide health problem, the world’s second-leading cause of death and third-leading cause of disability. Currently, the majority of stroke patients are ischemic stroke patients. It is necessary to evaluate risk factors to prevent ischemic stroke. Data and Methods: The risk factors for stroke in the previous fiscal year were analyzed. They were divided into nonmodifiable and modifiable factors. The probit and ordered probit models were used in the study, with 59341 and 50542 observations used in the estimation of the models, respectively. Results: Among the nonmodifiable factors, age, gender and cerebrovascular disease history are important risk factors. The history of cerebrovascular diseases is considered to be an especially important factor. Among the modifiable factors, taking antihypertensive drugs and recent large weight change are negative risk factors;however, sleeping well significantly reduces the probability of ischemic stroke. Conclusion: It is very important to ensure that medical personnel know a patient’s history of cerebrovascular diseases for proper treatments. Ischemic stroke might be considered an important side effect of antihypertensive drugs. Limitations: The dataset was observatory. There are various types of antihypertension drugs, and their effects are not analyzed. 展开更多
关键词 STROKE ISCHEMIC STROKE CEREBROVASCULAR History antihypertensive drug Side Effect
下载PDF
Synchronized separation of atorvastatin——an antihyperlipidemic drug with antihypertensive, antidiabetic, antithrombotic drugs by RP-LC for determination in combined formulations 被引量:1
3
作者 M.V.N.Kumar Talluri Anitha Kalyankar Srinivas Ragampeta 《Journal of Pharmaceutical Analysis》 SCIE CAS 2012年第4期285-292,共8页
A new rapid and sensitive high performance liquid chromatography (HPLC) method has been developed for the simultaneous determination of atorvastatin—an antihyperlipidemic drug along with most commonly prescribed drug... A new rapid and sensitive high performance liquid chromatography (HPLC) method has been developed for the simultaneous determination of atorvastatin—an antihyperlipidemic drug along with most commonly prescribed drugs (antihyperlipidemic, antihypertensive, antidiabetic, antithrombotic) in bulk and marketed combined formulations. The chromatographic separation was carried out by gradient elution mode with acetonitrile as organic modifier and 0.1% triethylamine acetate (TEAA) buffer pH 5 at a flow rate of 1 mL/min and a diode array detector at wavelength 230 nm was employed for detection of the analytes. Calibration curves were linear in the range of 5-150 mg/mL for all the drugs with correlation coefficients of determination (r 2 values)Z0.999. Limits of detection (LODs) and Limits of quantification (LOQs) ranged from 0.1 to 0.27 mg/mL and 0.3 to 0.89 mg/mL respectively. Intra-day and inter-day precision was studied at three concentration levels (20, 60 and 100 mg/mL). The intra-day and inter-day RSD for all compounds was less than 2.0%. The accuracy for all compounds was found to be between 98% and 102%. Thus, the performance of the method described allows its use in quantification of atorvastatin along with 9 most commonly prescribed drugs available in market as atorvastatin combined dosage forms. 展开更多
关键词 ATORVASTATIN RP-HPLC ANTIHYPERLIPIDEMIC antihypertensive ANTIDIABETIC Antithrombotic drug
下载PDF
An Analysis of the Effects of Blood Pressure and Antihypertensive Drugs on Heart Disease 被引量:2
4
作者 Kazumitsu Nawata Hayato Sugano Moriyo Kimura 《Health》 2019年第6期792-816,共25页
Background: The American College of Cardiology (ACC), American Heart Association (AHA) and other organizations announced a new hypertension guideline (2017 ACA/AHA Guideline) in November 2017. However, other organizat... Background: The American College of Cardiology (ACC), American Heart Association (AHA) and other organizations announced a new hypertension guideline (2017 ACA/AHA Guideline) in November 2017. However, other organizations such as the European Society of Cardiology and European Society of Hypertension maintained their diagnostic thresholds. It is necessary to evaluate the effects of blood pressure (BP) and antihypertensive drugs on the probability of having heart disease (HD). Data and Methods: The effects of BP, antihypertensive drugs and other factors on the probability of undergoing HD treatment were analyzed. We used a dataset containing 83,287 medical check-up and treatment records obtained from 35,504 individuals in 5 fiscal years. The probit models were used in the study. Considering the possibility of endogeneity problems, different types of models were used. Results: We could not find evidence that a higher systolic BP increased the probability of undergoing HD treatment. However, diastolic BP increased the probability in most of the models. Taking antihypertensive drugs also increased the probability of undergoing HD treatment. Diabetes was another important risk factor. Conclusion: The results of this study did not support the new 2017 ACC/AHA Guideline. It is necessary to choose proper drugs and methods to reduce the risks of side effects. Limitations: The dataset was observatory, the data were obtained from just one medical society, and sample selection bias might exist. 展开更多
关键词 HEART Disease 2017 ACC/AHA HYPERTENSION GUIDELINE HYPERTENSION Blood Pressure antihypertensive drug Diabetes
下载PDF
Synthesis of (2S,4S)-2-Substituted-3- (3-Sulfanylpropanoyl)-6- Oxohexahydropyrimidine-4-Carboxylic Acids as Potential Antihypertensive Drugs
5
作者 Andrei Ershov Dmitry Nasledov +1 位作者 Igor Lagoda Valery Shamanin 《Journal of Materials Science and Chemical Engineering》 2015年第6期7-12,共6页
Proceeding from natural amino acid L-asparagine and commercially available aldehydes a stereoselective synthesis was developed of (2S,4S)-2-alkyl(aryl)-3-(3-sulfanylpropanoyl)-6-oxohexahy- dropyrimidine-4-carboxylic a... Proceeding from natural amino acid L-asparagine and commercially available aldehydes a stereoselective synthesis was developed of (2S,4S)-2-alkyl(aryl)-3-(3-sulfanylpropanoyl)-6-oxohexahy- dropyrimidine-4-carboxylic acids, potential antihypertensive drugs, inhibitors of the angiotensin converting enzyme. 展开更多
关键词 Synthesis of (2S 4S)-2-Substituted-3- (3-Sulfanylpropanoyl)-6- Oxohexahydropyrimidine-4-Carboxylic ACIDS AS POTENTIAL antihypertensive drugs
下载PDF
Research on the World’s Most Valuable Antihypertensive Drugs Based on Patent Analysis
6
作者 Zhang Tianqi Chen Yuwen 《Asian Journal of Social Pharmacy》 2021年第1期76-83,共8页
Objective To find out several patented technologies of antihypertensive drugs with the most market value through analysis,and provide a reference for the research and development of enterprises.Methods The most valuab... Objective To find out several patented technologies of antihypertensive drugs with the most market value through analysis,and provide a reference for the research and development of enterprises.Methods The most valuable patented technologies of antihypertensive drugs from 2009 to 2019 were analyzed to explore the patent layout and technical characteristics of the main patent applicants,and then the key directions of their research and development were gotten.Results and Conclusion Based on the method of patent analysis,five patents with the most market value are extracted to provide important technical support and market value reference for the research and development of generic drugs or new drugs. 展开更多
关键词 antihypertensive drug patented generic drug patented technology market value
下载PDF
Twenty-four-hour ambulatory blood pressure changes in older patients with essential hypertension receiving monotherapy or dual combination antihypertensive drug therapy 被引量:2
7
作者 Pei-Pei LU Xu MENG +9 位作者 Ying ZHANG Yan-Qi LI Shu WANG Li-Sheng LIU Wen WANG Yu-Ling LI Yu-Qing ZHANG Ai-Hua HU Xian-Liang ZHOU Li-Hong MA 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2019年第4期354-361,共8页
Objective To evaluate the differences in 24-hour ambulatory blood pressure (BP) in older patients with hypertension treated with the five major classes of antihypertensive drugs,as monotherapy or dual combination ther... Objective To evaluate the differences in 24-hour ambulatory blood pressure (BP) in older patients with hypertension treated with the five major classes of antihypertensive drugs,as monotherapy or dual combination therapy,to improve daytime and nighttime BP control. Methods We enrolled 1920 Chinese community-dwelling outpatients aged ≥ 60 years and compared ambulatory BP values and ambulatory BP control (24-hour BP < 130/80 mmHg;daytime mean BP < 135/85 mmHg;and nighttime mean BP < 120/70 mmHg),as well as nighttime BP dip patterns for monotherapy and dual combination therapy groups. Results Patients’ mean age was 71 years,and 59.5% of patients were women. Calcium channel blockers (CCBs) constituted the most common (60.3% of patients) monotherapy,and renin–angiotensin system (RAS) blockers combined with CCBs was the most common (56.5% of patients) dual combination therapy. Monotherapy with beta-blockers (BB) provided the best daytime BP control. The probabilities of having a nighttime dip pattern and nighttime BP control were higher in patients receiving diuretics compared with CCBs (OR = 0.52,P = 0.05 and OR = 0.41,P = 0.007,respectively). Patients receiving RAS/diuretic combination therapy had a higher probability of having controlled nighttime BP compared with those receiving RAS/CCB (OR = 0.45,P = 0.004). Compared with RAS/diuretic therapy,BB/CCB therapy had a higher probability of achieving daytime BP control (OR = 1.27,P = 0.45). Conclusions Antihypertensive monotherapy and dual combination drug therapy provided different ambulatory BP control and nighttime BP dip patterns. BB-based regimens provided lower daytime BP,whereas diuretic-based therapies provided lower nighttime BP,compared with other antihypertensive regimens. 展开更多
关键词 Aging AMBULATORY blood pressure monitoring antihypertensive drugs BETA-BLOCKERS DIURETICS
下载PDF
Effect of Antihypertensive Drug Therapy on the Blood Pressure Control among Hypertensive Patients Attending Campus’ Teaching Hospital of Lome, Togo, West Africa
8
作者 Yao Potchoo Edem Goe-Akue +3 位作者 Findibe Damorou Barima Massoka Datouda Redah Innocent P. Guissou 《Pharmacology & Pharmacy》 2012年第2期214-223,共10页
High blood pressure (HBP) is a health problem world—wide. In Togo, that affection constitutes a more and more pre-occupying cause of morbidity and mortality. This study is a prospective one which intended to identify... High blood pressure (HBP) is a health problem world—wide. In Togo, that affection constitutes a more and more pre-occupying cause of morbidity and mortality. This study is a prospective one which intended to identify the antihypertensive regimens prescribed and evaluate their effect on patients’ blood pressure (BP) control. Out of the 204 patients enrolled (mean: 55.01 ± 12.55 years;sex ratio: 1.3), 112/176 placed on antihypertensive therapy have controlled their BP (38.39% outpatients vs 61.61% inpatients). Related to the sex factor, we didn’t observe any significant difference in the BP control. Whereas, the mean median value of BP reduction of outpatients (30.00/15.00 mmHg) (p = 0.001) was half lower than that of inpatients (60.00/30.00 mmHg (p = 0.004)). Thirty five outpatients (81.40%) vs 64 inpatients (92.75%) were placed on combination therapy. The bitherapy was prescribed to 23 outpatients (53.49%) against 27 inpatients (39.13%) while the quadritherapy and more than 4 drugs combination were prescribed exclusively to inpatients (20.29%, n = 14). That quadritherapy induced a significant mean reduction of inpatients’ SBP compared to monotherapy (p = 0.043) and to bitherapy (p = 0.004). The favorite combinations were D + CCA, D + ACEI, D + CCA + ACEI and D + CCA + ACEI + CAAD of which the quadruple therapy showed a significant inpatients’ DBP control (p = 0.015) compared to D + CCA combination. The combinations including at least one diuretic induced a significant difference between outpatients (median value: 30.000/10.000 mmHg) (p < 0.001) and inpatients (median value: 60.000 mmHg/30 mmHg) (p < 0.001). The first-line molecules and fixe combinations prescribed in decreasing frequency were among others: hydrochlorothiazide + captopril, nicardipine, α methyldopa for outpatients;furosemide, nicardipine, captopril, α methyldopa, hydrochlorothiazide + captopril for inpatients. Diuretics, CCAs and ACEIs were the 3 favorite pharmacological groups for essential hypertension management in our African resource limited context. Combined to CAAD, they represented the best quadruple combination among inpatients having showed a significant difference in DBP control compared to D + CCA combination. 展开更多
关键词 antihypertensive drugs Ambulatory PATIENTS Hospitalized PATIENTS Blood Pressure Control Prescription Monotherapy Bitherapy Tritherapy Quadritherapy CHU-Campus TOGO WEST AFRICA
下载PDF
Association between serum homocysteine and arterial stiffness:role of anti-hypertensive drugs 被引量:8
9
作者 Ercan Varol 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2014年第2期175-175,共1页
关键词 同型半胱氨酸 颈动脉 抗高血压药物 硬度 血清 心血管疾病 危险因素 老年人
下载PDF
Deprescribing antihypertensive treatment in nursing home patients and the effect on blood pressure 被引量:2
10
作者 Christine Gulla Elisabeth Flo +1 位作者 Reidun LS Kjome Bettina S Husebo 《Journal of Geriatric Cardiology》 SCIE CAS CSCD 2018年第4期275-283,共9页
BackgroundIt 是可争辩的与 antihypertensive 药对待 multimorbid 疗养院病人是否生产有益的效果。最心血管的指南支持治疗;很少有上的忠告到 deprescribe 当治疗可能不再是必要的时。我们在在认知,血压,和 prescribing.MethodsFrom... BackgroundIt 是可争辩的与 antihypertensive 药对待 multimorbid 疗养院病人是否生产有益的效果。最心血管的指南支持治疗;很少有上的忠告到 deprescribe 当治疗可能不再是必要的时。我们在在认知,血压,和 prescribing.MethodsFrom 2014年8月之间的 antihypertensive 药使用和协会上调查了药评论的效果到2015年12月,来自在 32 所挪威的疗养院的 72 个单位(簇)的 765 个病人被包括在一4月, multicentre ,使随机化簇的、控制试用,与9月的后续。病人们有 antihypertensive 治疗的 65 岁(n = 295, 39%) 被使随机化到医生从同伴(启蒙的 collegial ) 得到了支持或象往常一样被给照顾的系统的药评论(控制条件) 。结果措施是 antihypertensive 药,收缩血压,和脉搏的数字。我们把住院和死亡用作标准估计 harm.ResultsAt 基线,每个病人使用了 9.2 吗?? 展开更多
关键词 疗养院 血压 治疗 控制条件 随机化 收缩 基线 心血管
下载PDF
中国肾脏移植受者高血压临床诊疗指南
11
作者 中华医学会器官移植学分会 张健 +4 位作者 林俊 胡小鹏 丁小明 李宁 薛武军 《器官移植》 CAS CSCD 北大核心 2024年第4期509-532,共24页
为了进一步规范中国肾脏移植术后高血压的诊断和治疗,中华医学会器官移植学分会组织肾脏移植专家和心血管病专家,在《中国实体器官移植术后高血压诊疗规范(2019版)》的基础上,结合我国器官移植后高血压的临床现状,并参考近年国内外高血... 为了进一步规范中国肾脏移植术后高血压的诊断和治疗,中华医学会器官移植学分会组织肾脏移植专家和心血管病专家,在《中国实体器官移植术后高血压诊疗规范(2019版)》的基础上,结合我国器官移植后高血压的临床现状,并参考近年国内外高血压最新诊治指南,从流行病学、诊断和治疗等方面,制定《中国肾脏移植受者高血压临床诊疗指南》,为中国肾脏移植领域医务工作者在术后高血压诊治方面提供理论借鉴和参考,以期更好地控制肾脏移植术后成人高血压,改善不良结局,提高生命质量。 展开更多
关键词 肾脏移植 高血压 心血管事件 慢性肾病 难治性高血压 免疫抑制药 排斥反应 降压药
下载PDF
围手术期高血压的管理与控制
12
作者 成硕 谢菡 +2 位作者 邵腾飞 周思敏 葛卫红 《医药导报》 CAS 北大核心 2024年第9期1444-1450,共7页
围手术期未得到控制的高血压可能影响患者手术中血流动力学稳定性,进而影响患者预后,增加其他并发症出现和死亡的风险。对于接受手术的高血压患者,都需要权衡利弊选择合适的降压药物来降低围手术期不良事件的发生率。目前我国对围手术... 围手术期未得到控制的高血压可能影响患者手术中血流动力学稳定性,进而影响患者预后,增加其他并发症出现和死亡的风险。对于接受手术的高血压患者,都需要权衡利弊选择合适的降压药物来降低围手术期不良事件的发生率。目前我国对围手术期血压的管理尚无统一定论,该文从非心脏手术、心脏手术、妊娠、嗜铬细胞瘤4个手术类型系统梳理围手术期血压的控制目标与药物使用方案,为高血压患者的围手术期管理提供参考。 展开更多
关键词 围手术期 血压管理 抗高血压药物 围手术期用药
下载PDF
集采政策对医疗机构心血管药品采购的影响研究
13
作者 段凤然 文小桐 +5 位作者 王越 刘雨欣 罗佳 杨赐然 金雅磊 毛宗福 《卫生经济研究》 北大核心 2024年第3期69-73,共5页
目的:分析药品集采政策对不同等级医疗机构心血管药品采购的影响,为药品集采政策的调整与优化提供参考。方法:分析心血管药品在各级医疗机构的采购量变化情况,采用Mann-Kendall(M-K)趋势性检验判断心血管药品采购量的长期变化趋势。结果... 目的:分析药品集采政策对不同等级医疗机构心血管药品采购的影响,为药品集采政策的调整与优化提供参考。方法:分析心血管药品在各级医疗机构的采购量变化情况,采用Mann-Kendall(M-K)趋势性检验判断心血管药品采购量的长期变化趋势。结果:药品集采政策实施后,心血管药品中选产品采购量大幅增长;各级医疗机构集采品种采购量增幅随采购周期的延长而降低;试点地区基层医疗机构中选产品采购量显著增长,联盟地区仅基层医疗机构非中选产品采购量显著下降,基层医疗机构可替代品种采购量呈下降趋势。结论:药品集采政策效应可能存在滞后性,且随采购周期的延长而逐渐弱化,可替代品种的采购量增长值得进一步关注。 展开更多
关键词 药品集中带量采购 分级诊疗 基层医疗机构 降压药 调脂药
下载PDF
国家组织药品集中带量采购政策对某院门诊药房降压药物使用的影响分析
14
作者 王茂 郑明琳 +3 位作者 何璐璐 王世燕 高洋洋 樊萍 《中国药业》 CAS 2024年第5期14-18,共5页
目的探讨国家组织药品集中带量采购(简称国家集采)政策对某院门诊患者降压药物使用情况的影响。方法以医院门诊药房国家集采政策实施前(2018年1月至12月)及实施后(2020年1月至12月)23种降压药物为目标药品,共涉及10种中选品种;利用医院... 目的探讨国家组织药品集中带量采购(简称国家集采)政策对某院门诊患者降压药物使用情况的影响。方法以医院门诊药房国家集采政策实施前(2018年1月至12月)及实施后(2020年1月至12月)23种降压药物为目标药品,共涉及10种中选品种;利用医院信息系统收集目标药品的价格、销售数量和金额,比较用药频度(DDDs)、限定日费用(DDC)。结果国家集采政策实施后,其中11种降压药物的价格降幅为5.86%~89.70%,23种降压药物的销售金额累计减少2705.60万元。DDDs排名前3的目标药品未发生变化,为苯磺酸氨氯地平片(商品名洛活喜)、富马酸比索洛尔片(商品名康忻)、坎地沙坦酯片(商品名维尔亚);10种中选品种的DDDs排名均居前列。DDC排名前4的目标药品未发生变化,为厄贝沙坦氢氯噻嗪片(商品名安博诺)、厄贝沙坦片(商品名安博维)、缬沙坦胶囊(商品名代文)、氯沙坦钾片;10种中选品种的DDC相对较低,且非中选品种的DDC均降低。结论国家集采政策的实施促使药品价格趋于合理,减轻了患者用药的经济负担,优化了医保资金的使用,提高了医疗保障水平。 展开更多
关键词 国家组织药品集中带量采购 门诊药房 降压药物 用药频度 限定日费用
下载PDF
2023美国心脏协会癌症治疗相关高血压科学声明解读
15
作者 韩丽珠 尹琪楠 +4 位作者 边原 吕子彦 黄雪飞 雷洋 陈岷 《医药导报》 北大核心 2024年第2期155-160,共6页
2023年1月,美国心脏协会(AHA)发布癌症治疗相关高血压科学声明,对其发病机制和临床管理进行综述。现代抗癌治疗多以心血管毒性为代价,其中高血压是最常见的副作用之一,尤其是血管内皮生长因子抑制剂、酪氨酸激酶抑制剂和蛋白酶体抑制剂... 2023年1月,美国心脏协会(AHA)发布癌症治疗相关高血压科学声明,对其发病机制和临床管理进行综述。现代抗癌治疗多以心血管毒性为代价,其中高血压是最常见的副作用之一,尤其是血管内皮生长因子抑制剂、酪氨酸激酶抑制剂和蛋白酶体抑制剂。癌症治疗相关高血压通常是剂量限制性,并且在中断或停止治疗后通常是可逆的。高血压的确切分子机制尚不清楚,近期研究表明,一氧化氮减少、内皮素-1增加、氧化应激、内皮功能障碍、交感神经外流增加和微血管稀疏具有重要作用。结合国际心脏肿瘤学会(IC-OS)的建议,该文对癌症治疗相关高血压的诊断及管理进行解读,目前尚无针对癌症治疗相关高血压患者的降压药物循证证据,故遵循普通人群高血压指南,并且需要多学科合作优化管理,以确保癌症治疗的最佳治疗效果,同时最大限度地减少心血管毒性。 展开更多
关键词 抗高血压药物 癌症治疗 高血压
下载PDF
口腔苔藓样药物反应的研究进展
16
作者 黎希晔 葛姝云 唐国瑶 《口腔疾病防治》 2024年第7期555-561,共7页
口腔苔藓样药物反应(oral lichenoid drug reactions,OLDR)是特殊体质者使用特定药物后引起的口腔黏膜炎性反应,属于口腔苔藓样损害(oral lichenoid lesions,OLL)这一病种,其临床表现和病理表现与其他种类的OLL相比不存在明显的特异性,... 口腔苔藓样药物反应(oral lichenoid drug reactions,OLDR)是特殊体质者使用特定药物后引起的口腔黏膜炎性反应,属于口腔苔藓样损害(oral lichenoid lesions,OLL)这一病种,其临床表现和病理表现与其他种类的OLL相比不存在明显的特异性,可能诱发OLDR的药物种类繁多,包括了降压药、非甾体抗炎药、降糖药、抗焦虑/精神类药物、生物制剂等,治疗方案除局部或全身使用糖皮质激素以外,停用可疑药物是最有效的治疗措施,大多数患者的黏膜溃疡、糜烂能得到较大缓解,但可能仍有白纹残留。虽然OLDR已在文献报道和临床工作中得到广泛关注,但由于缺乏系统的认识,对于OLDR的诊断并没有公认的标准,也缺乏规范化的诊疗流程,且相关药物与口腔苔藓样病变之间的因果关系仍然存在疑问。针对以上问题,笔者检索了近20年国内外药物相关口腔扁平苔藓和苔藓样损害的文献,其中绝大多数为病例报告,仅有少量病例对照研究。本文从相关概念、可疑药物、临床及病理表现、治疗预后4个方面介绍了其研究现状,希望能为相关苔藓样损害的预防、诊断和临床治疗提供理论参考。文献综述显示了该疾病在病因、发病机制、临床诊疗、治疗预后等方面仍有大量问题尚不明确,仍需进一步开展临床及基础研究予以深入探索。 展开更多
关键词 口腔扁平苔藓 口腔苔藓样药物反应 苔藓样反应 苔藓样疹 降压药 非甾体类抗炎药 降糖药 免疫抑制剂
下载PDF
糖尿病综合管理中的药物相互作用调查与分析
17
作者 马雪辰 沈珑 +2 位作者 俞彬滨 曹莉华 施芳红 《中国药业》 CAS 2024年第8期115-120,共6页
目的分析糖尿病综合管理中药物相互作用(DDI)的特点及影响因素。方法使用Lexi-InteractTM数据库,筛选糖尿病综合管理中降血糖药、降血压药、调血脂药、减重药的DDI,根据严重程度分为X级(避免联用)、D级(考虑调整治疗)、C级(需监控治疗)... 目的分析糖尿病综合管理中药物相互作用(DDI)的特点及影响因素。方法使用Lexi-InteractTM数据库,筛选糖尿病综合管理中降血糖药、降血压药、调血脂药、减重药的DDI,根据严重程度分为X级(避免联用)、D级(考虑调整治疗)、C级(需监控治疗)、B级(无须调整)、A级(无DDI);收集上海某三级甲等医院2型糖尿病并心肌梗死患者的病例资料,并根据患者的DDI数量分为低DDI组(<5组DDI)和高DDI组(≥5组DDI),分析DDI的特点及影响因素。结果共纳入109种药物,其中降血压药、降血糖药、调血脂药、减重药分别有57种、32种、19种、1种,DDI分别有5091组、1086组、723组、15组。除减重药外,其余3种药物DDI总数最多的分别为钙通道阻滞剂(CCB)、磺脲类药物、他汀类药物;X级药物DDI数量排名前3的药物分别为他汀类药物、CCB类药物及β受体拮抗药。共纳入患者69例,其中低DDI组和高DDI组分别有26例、43例,影响患者DDI总数的危险因素包括患者合并用药数量、慢性肾脏病(CKD)1-3期,以及糖化血红蛋白、糖化白蛋白和空腹血糖水平(P<0.05)。结论控制合并用药数量并保持良好的血糖水平,有利于减少糖尿病综合管理中的DDI。 展开更多
关键词 糖尿病 综合管理 降血糖 调血脂 降血压 体质量 药物相互作用 危险因素
下载PDF
不同降压药物治疗原发性高血压患者血压变异的研究进展
18
作者 黄胜楠 方超 +1 位作者 吴剑南 肖暖 《心脏杂志》 CAS 2024年第4期442-445,451,共5页
血压变异性是心、脑血管疾病及肾脏损伤的独立危险因素,并在其发生、发展及严重程度方面较平均动脉压具有更高的预测价值,同时也是评价降压药物疗效的重要指标之一。所以早期判断高血压患者的血压变异情况并对其进行积极干预,防止心脑... 血压变异性是心、脑血管疾病及肾脏损伤的独立危险因素,并在其发生、发展及严重程度方面较平均动脉压具有更高的预测价值,同时也是评价降压药物疗效的重要指标之一。所以早期判断高血压患者的血压变异情况并对其进行积极干预,防止心脑血管事件的进一步发展已成为高血压管理过程中的重要环节。本文将从血压变异性的定义及分类、控制血压变异性的意义以及常见降压药物的疗效观察这几个方面展开综述。 展开更多
关键词 血压变异性 高血压 抗高血压药物 联合用药
下载PDF
高境镇社区卫生服务中心2017—2022年抗高血压药物使用情况调查分析
19
作者 陈云峰 薛良 《上海医药》 CAS 2024年第2期11-16,共6页
目的 :对上海市宝山区高境镇社区卫生服务中心抗高血压药物的使用情况开展调查分析。方法 :通过中心医院管理信息系统查询并采集2017-2022年间开具的抗高血压药物名称、分类、规格、价格和使用数量等信息,进行汇总分析。结果 :疫情前中... 目的 :对上海市宝山区高境镇社区卫生服务中心抗高血压药物的使用情况开展调查分析。方法 :通过中心医院管理信息系统查询并采集2017-2022年间开具的抗高血压药物名称、分类、规格、价格和使用数量等信息,进行汇总分析。结果 :疫情前中心共使用6类、40个品规的抗高血压药物,药物使用总金额为27 786 452.20元,总用药频度为13 567 287.00;疫情期间中心共使用7类、45个品规的抗高血压药物,药物使用总金额为26 418 566.08元,总用药频度为15 806 762.33。疫情前与疫情期间中心抗高血压药物的用药频度排序结果相同,均依次为钙通道阻滞剂、血管紧张素Ⅱ受体抑制剂、单片复方制剂、β受体拮抗剂、血管紧张素转换酶抑制剂、利尿剂和其他。疫情前中心抗高血压药物按使用总金额排序依次为钙通道阻滞剂、血管紧张素Ⅱ受体抑制剂、单片复方制剂、β受体拮抗剂、血管紧张素转换酶抑制剂、利尿剂和其他,疫情期间中心抗高血压药物按使用总金额排序依次为钙通道阻滞剂、单片复方制剂、血管紧张素Ⅱ受体抑制剂、β受体拮抗剂、其他、利尿剂和血管紧张素转换酶抑制剂。结论 :应及时在药物保障与管理上进行调整,加强社区医务人员的相关药物治疗管理培训,同时通过培养或引进专业性强、业务能力突出的执业药师开展合理用药指导。 展开更多
关键词 社区卫生服务中心 抗高血压药物 药物使用情况
下载PDF
杂粮饮食结合降压药对高血压患者的干预效果 被引量:1
20
作者 吴春梅 《中国医药指南》 2024年第12期43-45,共3页
目的探究杂粮饮食结合降压药对高血压患者的干预效果。方法选取2020年7月至2022年7月在本社区卫生服务中心进行常规治疗的高血压患者70例作为本次分析对象,采用随机抽样法分为两组,各35例,对照组采用常规降压药干预,观察组采用杂粮饮食... 目的探究杂粮饮食结合降压药对高血压患者的干预效果。方法选取2020年7月至2022年7月在本社区卫生服务中心进行常规治疗的高血压患者70例作为本次分析对象,采用随机抽样法分为两组,各35例,对照组采用常规降压药干预,观察组采用杂粮饮食结合降压药干预。对两组患者的血压控制情况、血脂情况以及患者满意度情况进行对比分析,探究其应用效果。结果干预后,观察组血压控制水平低于对照组(P<0.05);观察组TC、TG以及LDL-G水平低于对照组,HDL-C值高于对照组(P<0.05);且护理满意度,观察组高于对照组(P<0.05)。结论对于高血压患者,采用杂粮饮食结合降压药的干预方式可提升患者的治疗效果,改善患者血脂水平,降低并发症发生率;同时可稳定患者血压水平,提升患者满意度。 展开更多
关键词 高血压 杂粮饮食 降压药 血压水平
下载PDF
上一页 1 2 44 下一页 到第
使用帮助 返回顶部